Feedback
Antimicrobial Susceptibility - Surveillance Carbapenemase Gene Detection by PCR
2014284
Ordering Recommendation

Detect the presence of predominant carbapenemase genes (blaKPC, blaNDM, blaVIM, blaOXA-48, blaIMP) responsible for resistance to carbapenem and other beta-lactam antibiotics. Test is performed on rectal swab specimen.

Mnemonic
CARBA SWAB
Methodology
Qualitative Polymerase Chain Reaction
Performed
Sun-Sat
Reported
1-4 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Rectal eSwab. Refer to collection instructions at https://www.aruplab.com/Specimen-Handling/resources/pdf/rectal-eswab.pdf 
Specimen Preparation
Transport rectal swab in eSwab transport media (ARUP Supply #45877) available online through eSupply using ARUP ConnectTM or contact ARUP Client Services at (800) 522-2787. Place each specimen in an individually sealed bag. 
Storage/Transport Temperature
Refrigerated. Also acceptable: Frozen. 
Unacceptable Conditions
 
Remarks
Specimen source required. 
Stability
Ambient: 48 hours; Refrigerated: 6 days; Frozen: 6 days 
Reference Interval
Not Detected
Interpretive Data
This assay detects five carbapenemase gene families (blaKPC, blaNDM, blaOXA-48, blaVIM, blaIMP) encoding enzymes that may confer resistance to carbapenem and other beta-lactam antibiotics. This assay is intended for use as an aid to infection control in the detection of carbapenem-resistant bacteria and is not intended to guide or monitor treatment of infection. A negative result does not exclude the presence of other resistance mechanisms or assay-specific nucleic acid in concentrations below the level of detection.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
This assay will generate a negative IMP result when testing samples containing IMP-7, IMP-13 or IMP-14 gene sequences, and may detect IMP-4 at reduced sensitivity. False-negative results may be encountered in rectal specimens with Pseudomonas aeruginosa containing the blaVIM gene and with Acinetobacter baumanii containing blaIMP gene.
Hotline History
View Hotline History
Components
Component Test Code*Component Chart NameLOINC
2014278KPC gene by PCR49617-4
2014279NDM gene by PCR73982-1
2014280OXA-48 gene by PCR63368-5
2014281VIM gene by PCR63368-5
2014282IMP gene by PCR63368-5
2014283CarbaR Interpretation48767-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • carbapenem-resistance
  • carbapenemase
  • CRE
  • Enterobacteriaceae
  • IMP
  • Klebsiella pneumoniae carbapenemase
  • KPC
  • MDR
  • multi-drug resistance
  • NDM
  • NewDelhi metallo-B-lactamase
  • OXA-48
  • resistance mechanism
  • VIM